StratumSkin science, cited
Ingredient Index

Pigmentation

Iron oxides

Tinted mineral sunscreen pigment

Overall grade BTypical strength Present in most 'tinted' mineral or hybrid sunscreens; concentration rarely disclosed3 sources

A plain SPF number only describes UV protection. Iron oxides are what give a sunscreen its tint, and that tint is also what blocks visible light, including the blue-violet end of the spectrum that ordinary UV filters let straight through. That distinction matters specifically for melasma and post-inflammatory dark marks, which visible light can trigger and worsen on its own, sunburn or not. This isn't a stand-alone treatment: it only adds anything on top of a real UV filter, and it does nothing for the vascular or structural causes of dark under-eye circles or any pigmentation unrelated to melanin.

Claim by claim

BBoosts hydroquinone's effect on active melasmaAn independent randomised trial gave everyone 4% hydroquinone and randomised only the sunscreen: over 8 weeks, the group using a visible-light-blocking, iron-oxide-tinted sunscreen improved 15% more on MASI score, 28% more on colorimetry and 4% more on melanin index than the group using a UV-only sunscreen with the same hydroquinone regimen.
CReduces melasma relapse after treatmentA different, narrower question with thinner support: only one trial has specifically tested relapse after melasma clears, and it's an industry-funded one (a company that sells tinted sunscreen, with an employee as co-author) showing less worsening over 6 months with tinted versus UV-only sunscreen. A 2025 trial from an overlapping author points the same way but isn't an independent replication, since it shares the funding line. Directionally consistent, not independently confirmed.

References

  1. Castanedo-Cazares JP, Hernandez-Blanco D, Carlos-Ortega B, Fuentes-Ahumada C, Torres-Álvarez B. Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. Photodermatology, Photoimmunology & Photomedicine, 2014.BDouble-blind randomised trial, n=68·This is a treatment trial, not a relapse-prevention one: all 68 participants used 4% hydroquinone for 8 weeks, and only the accompanying sunscreen (UV-only vs. UV+visible-light-blocking) was randomised. We could not find any funding or industry tie for this trial in available sources, which is a point in its favour, though we could not positively confirm a 'no funding' statement either, only that no tie surfaced.PubMed 24313385DOI 10.1111/phpp.12086
  2. Boukari F, Jourdan E, Fontas E, Montaudié H, Castela E, Lacour JP, Passeron T. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. Journal of the American Academy of Dermatology, 2015.CProspective randomised comparative trial, n=39 analysed·The only trial we found that actually tests relapse specifically, rather than treatment of active melasma. Funded by Laboratoire Bioderma; co-author Eric Jourdan is a Bioderma employee, and this is a tinted-sunscreen product Bioderma sells. Median MASI (melasma severity score) increase at 6 months was 0.45 with the tinted formula versus 2.43 with UV-only sunscreen (p=0.027) — a real and fairly large gap, but from a funded source with no independent replication of the relapse-specific finding.PubMed 25443629
  3. Polena H, Queille-Roussel C, Graizeau C, Duteil L, Sayag M, Passeron T. Comparison of Visible Light-Protective Tinted Sunscreen to Untinted Sunscreen to Protect Melasma Patients During Summer: A Prospective Randomized Investigator-Blinded Study. Journal of Cosmetic Dermatology, 2025.CProspective randomised, investigator-blinded trial·Three of six authors are employees of NAOS (Bioderma's parent company); the senior author also co-authored the 2015 Bioderma-funded trial above. Directionally consistent with it, but this is the same funding line reinforcing itself, not an independent replication.PubMed 41014037

Your turn

Did this hold up? Tell us honestly — especially if it didn’t.

Anonymous. Stored in your browser.

The Sunday study

One paper a week, explained properly

We pick a single new study, tell you what it measured, how many people it measured it in, and whether it should change anything you're doing — plus the two articles we published that week. No panic, and no hype.

We don't recommend products yet. When we do, they'll be things you can actually buy in India, any affiliate link will be labelled as one, and a commission will never buy a recommendation.

One email each Sunday. Unsubscribe in one click.